Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression: A randomized, double‐blind, placebo‐controlled trial

Difelikefalin, a selective kappa opioid receptor agonist designed to limit central nervous system (CNS) penetration, is under development for the treatment of pruritus. Its hydrophilic, small‐peptidic structure limits CNS entry, minimizing potential CNS‐mediated adverse events (AEs). This study asse...

Descripción completa

Detalles Bibliográficos
Autores principales: Viscusi, Eugene R., Torjman, Marc C., Munera, Catherine L., Stauffer, Joseph W., Setnik, Beatrice S., Bagal, Sukirti N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504812/
https://www.ncbi.nlm.nih.gov/pubmed/33982405
http://dx.doi.org/10.1111/cts.13042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504812/
https://www.ncbi.nlm.nih.gov/pubmed/33982405
http://dx.doi.org/10.1111/cts.13042

Ejemplares similares